secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001453687-25-000119
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian Q3 net loss $35.9M; cash $145.1M; AURORA trial on track
-----------------------------------------------------------------

- Net loss of $35.9M ($1.38/share) vs $24.2M ($1.13/share) in Q3 2024.
- Cash, equivalents and restricted cash $145.1M, expected to fund ops into mid-2027.
- Phase 3 AURORA enrollment on track; ~100 participants, primary endpoint at Month 4.
- Preliminary Phase 2 SLE data and pediatric basket trial initiation expected by end of 2025.
- R&D expense $13.8M (+21% YoY) due to AURORA trial and headcount growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000119/0001453687-25-000119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000145368725000119/rnac-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001453687-25-000119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer